Navigation Links
Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
Date:4/23/2013

Valeant expects to complete the tender offer and consummate the merger promptly after the AMC's approval of the acquisition is received.  Except for the extension of the offer expiration date, all other terms and conditions of the offer remain unchanged. Stockholders who have already tendered their shares of common stock of Obagi do not have to re-tender their shares or take any other action as a result of the extension of the expiration date of the offer.

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Statements
This press release contains forward-looking statements regarding, among other things, the proposed acquisition by Valeant of Obagi, satisfaction of closing conditions and the timing of closing.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements.  Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect the proposed business combination of the companies and could cause actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the risk that the acquisition will not close when expected or at all; the risk that Valeant's business and/or Obagi's business will be adversely impacted during t
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
2. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
3. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
4. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
5. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
6. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
7. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
8. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
9. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
10. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
11. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... October 27, 2014 The ... produce, exhibit and sell its artificial "lower limb", ... their patent.      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ... of fighting, the definitive judgement has arrived: Roadrunnerfoot, ... innovative and accessible hi-tech prostheses with composite materials, ...
(Date:10/27/2014)... October 27, 2014 New Q4-2014 ... SoundConnect , an industry leading unified communication and ... and agents to deliver cloud-based audio and web/video ... opportunities. , With SoundConnect’s Q4 incentive partners ... video and/or web conferencing licenses sold, now through ...
(Date:10/27/2014)... , Oct. 27, 2014 Janssen Biotech, ... America (CCFA) announced today the launch of ... an educational campaign designed to provide resources ... on the paired role of nutrition and appropriate ... the multimedia assets associated with this release, please ...
(Date:10/25/2014)... 2014 The report “Adipic Acid ... Geography - Global Trends & Forecast to 2019” ... to market drivers, opportunities, and trends in different ... 27 figures spread through 217 slides and in-depth ... & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , Early ...
Breaking Biology Technology:Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2SoundConnect Unveils Q4 Partner Incentives 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4
... ROCKVILLE, Md., Aug. 6 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: ... and commercialization of clinical-stage product candidates for central nervous system disorders, ... 30, 2009, on Monday, August 10, 2009, before the market opens. ... that time. , , Mihael H. Polymeropoulos, M.D., ...
... , , BRISBANE, Calif., Aug. ... operations for the second quarter and six months ended June 30, 2009. ... of $36.7 million, or $0.81 per share, compared with a net loss of ... , , Dan Welch, Chairman, Chief Executive Officer and ...
... , , EMERYVILLE, Calif., Aug. ... added John E. Sealander, AIA, ACHA, NCARB, LEED(R) AP, as ... ( http://www.ratcliffarch.com ) provides a broad ... civic clients throughout the Western United States. , , ...
Cached Biology Technology:Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009 2InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 2InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 3InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 4InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 5InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 6InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 7InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 8InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 9InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 10InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 11InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 12InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 14InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 15Ratcliff Adds Architect John Sealander to Healthcare Practice Group 2
(Date:10/30/2014)... developed a suite of technologies that can be used ... applications in everything from search and rescue to service ... platform for computer-mediated communication between humans and dogs that ... behavioral signals and sending them clear and unambiguous cues ... of computer science at NC State and co-lead author ...
(Date:10/29/2014)... In the largest study of its kind to date, ... genes that heighten the risk for autism. Joseph Buxbaum, ... York City, Mark Daly, Ph.D., Broad Institute of Harvard ... DNA samples from affected children, parents and unrelated people. ... to contribute to the risk for autism spectrum disorder ...
(Date:10/29/2014)... number of chemicals from household and industrial products are ... bodies. But for most of them, scientists have yet ... taken the first step toward doing that by estimating ... new method is published in the ACS journal ... and colleagues note that the risks to human health ...
Breaking Biology News(10 mins):New tech aims to improve communication between dogs and humans 2
... adequate levels of vitamin D can help people breathe better ... recent study accepted for publication in The Endocrine Society,s ... The study of more than 10,000 Korean adults found ... D into their bodies. Vitamin D is absorbed primarily through ...
... tide this spring and summer, report NOAA-funded scientists studying the ... The "red tide" is caused by an alga Alexandrium ... shellfish poisoning (PSP). Red tide typically occurs annually along ... year,s outlook is similar to the 2012 red tide which ...
... sort of mathematical model used to predict which websites people ... helping map how lung cancer spreads in the human body, ... Cancer Research . A team of researchers used an ... Algorithm for digital communication to analyze the spread patterns of ...
Cached Biology News:Vitamin D benefits breathing in tuberculosis patients 2Researchers issue forecast for 'moderate' New England red tide in 2013 2New lung cancer study takes page from Google's playbook 2
GOAT ANTI CARICA PAPAYA PAPAIN...
IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
ANTI MYCOBACTERIUM TUBERCULOSIS...
Biology Products: